ct-868
Type 1 Diabetes
Carmot Therapeutics, Inc.Phase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Type 1 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Heba M. Ismail | Phase 4 | A |
Liraglutide Dasman Diabetes Institute | Phase 4 | BBB |
Tirzepatide Royal North Shore Hospital | Phase 4 | BBB |
Semaglutide Nordsjaellands Hospital | Phase 3 | BB |
Miglitol | Phase 3 | BB |
View all 23 →
Same molecule, other indications
ct-868 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →